Janssen Presents Longer-Term Talquetamab Follow-Up Data : co

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...

Related Keywords

Chicago , Illinois , United States , Belgium , Spain , Salamanca , Castillay Leóp , Beerse , Region Flamande , American , Talquetamab Monotherapy , Maria Victoria Mateos , Edmond Chan , Chris Heuck , Janssen Pharmaceutical Companies Of Johnson , None Of The Janssen Pharmaceutical Companies , American Society Of Clinical Oncology , European Commission Grants Marketing Authorisation , Companies Of Johnson , American Cancer Society , European Medicines Agency , Exchange Commission , Johnson , University Hospital Of Salamanca , Eastern Cooperative Oncology Group , Janssen Biotech Inc , Receptor Familyc Group , Janssen Research Development , American Society Of Hematology , Janssen Pharmaceutical Companies , Clinical Oncology , Annual Meeting , Senior Director , Area Lead Haematology , Humoral Immunity , Evaluating Talquetamab , Consultant Physician , University Hospital , Global Medical Head , Janssen Research , Part One , Breakthrough Therapy Designation , Orphan Drug Designation , Janssen Biotech , Pharmaceutical Companies , Infectious Diseases , Janssen Cilag Limited , Private Securities Litigation Reform Act , Janssen Pharmaceutica , Janssen Pharmaceutical , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Refractory Multiple , Patients With , Refractory Multiple Myeloma , Oral Presentation , American Society , Escalation Study , Participants With Relapsed , Subcutaneous Daratumumab Regimens , Participants With Multiple , Bispecific Antibody , Teclistamab Each , Combination With , Programmed Cell Death , Study Comparing Talquetamab , Combination With Daratumumab , Pomalidomide Versus Daratumumab , Combination With Pomalidomide , Participants With Multiple Myeloma , Commission Grants Marketing Authorisation , Subcutaneous Formulation , Dexamethasone Versus Bortezomib , Patients With Previously Treated Multiple Myeloma , Three Year Follow Up , Lymphoma Myeloma , Today Population Factsheets , Janssen Emea ,